As a forum for the exchange of information in the field of cancer immunology, Cancer Immunity provides rapid publication of original research, retrospectives, methods, and opinion pieces.

Cancer Immunity publishes papers in the following categories:

• Articles describing the results of original laboratory and clinical research.
  

• Reviews providing critical and balanced views of specific topics.
  

• Commentaries discussing papers recently published in Cancer Immunity or other journals. In addition, Cancer Immunity welcomes Commentaries dealing with any matter of importance to tumor immunology and immunotherapy.
  

• Reflections presenting a personal perspective on the origins and history of the field of tumor immunology by leaders in the field. Reflections are invited by the editors.

Reader's comments on papers are compiled and linked to the original publication to further scientific discussion. Please refer to the "Comment(s)" feature in the original publication to see how to submit such comments.

Please read all guidelines carefully and follow them strictly to ensure that the processing and publication of your manuscript is as efficient as possible. For further guidance, please do not hesitate to contact the Editorial Office.

Editorial Policies

Prior Publication
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Reporting of findings to the mass media may also preclude a paper from publication. Exception will be made for abstracts and oral presentations from scientific meetings published as part of the meeting's proceedings. If previously published tables, illustrations, or more than 200 words of text are to be included, the copyright holder's written permission must be obtained for online use and must accompany the accepted manuscript.

Conflicts of Interest
Any relationships, financial or otherwise, that might lead to a conflict of interest must be disclosed to the Editorial Office at the time of submission.

Materials and Data Deposition
Submission of manuscripts describing unique research materials (e.g. chemical and biological reagents, databases) implies that these will be made available for noncommercial purposes to all qualified investigators upon request. GenBank/EMBL/DDBJ database accession numbers for new sequence data must be supplied for publication.

Clinical Trial Registration
Clinical trial information must be deposited into a public clinical trial registry before the onset of patient enrollment. Please refer to the International Committee of Medical Journal Editors guidelines at http://www.icmje.org/publishing_10register.html.

Copyright
Authors will retain the copyright to any material they publish in the journal. Copyright to articles published in the journal will be attributed to the corresponding author as the authors' representative (unless otherwise requested). While retaining copyright, authors agree to acknowledge Cancer Immunity as the original place of publication in all future publications and as the copyright holder to the collective work. For the copyright terms of use, please refer to the journal's copyright notice.

Author Self-Archiving Policy
Authors can post material submitted to the journal on personal web sites or institutional repositories after publication provided that Cancer Immunity is acknowledged as the original place of publication. A number of funding agencies (NIH, HHMI, UKPMC funders) now require that the research they fund be deposited in a public registry. As Cancer Immunity participates in PubMed Central, authors need not submit the final peer-reviewed manuscript themselves to the appropriate registry upon acceptance of their manuscript for publication.

Liability
No liability is accepted for loss or damage of materials submitted. Authors should keep a copy of all files.

Manuscript Submission

Cancer Immunity accepts manuscripts contributed directly by Members of the Academy of Cancer Immunology and welcomes manuscripts by non-Members.

Manuscripts contributed by Members of the Academy of Cancer Immunology are accepted upon submission. It is the Member's responsibility to have the manuscript reviewed by two colleagues outside his or her institution before it is submitted. The Member should provide the names of the reviewers at the time of submission.

Non-Members of the Academy may submit manuscripts to a Member of the Academy OR to the Editorial Office. Manuscripts not submitted directly to a Member will be assigned to one by the Editorial Office. Authors may include suggestions of Members whose expertise would make them suitable editors. Authors should also provide names of reviewers to exclude for conflicts of interests. Whether a manuscript is submitted to a Member, or assigned to a Member by the Editorial Office, the Member will be responsible for having the manuscript reviewed by two individuals knowledgeable in the area. Reviewers may or may not be Academy Members.

Please review the scope of the journal to ensure that the journal is the appropriate place to publish your work. Manuscripts will be evaluated based on the contribution of original material that is likely to be of interest to readers involved in cancer immunology. Editorial comments will be communicated to the contributor at the discretion of the Editorial Board.

Articles contributed directly by Members of the Academy are distinguished in the journal as "Contributed by". Articles by non-Member authors are distinguished in the journal as "Communicated by" [the editor responsible for the review process].

A non-Member manuscript that is rejected by the journal may not be resubmitted by a Member.

Preparation

DOWNLOAD INSTRUCTIONS FOR AUTHORS (PDF)

Manuscripts should be submitted via e-mail to cancerimmunity@cancerimmunity.org. In exceptional cases, the initial manuscript submission may be in hard-copy format - please contact the Editorial Office for instructions.

Manuscripts should be submitted as a single text file containing the text and figure legends. Text files in RTF (rich text format) or Microsoft Word DOC format are preferred. Other standard word processing file formats will also be accepted. Manuscript text should be in Arial or Helvetica font face, size 12 pt, and double-spaced.

Each table and figure must be submitted as a separate file, and labeled correctly. Tables should be submitted as a Microsoft Word DOC, or as images. All images should be in TIFF format and have a minimum resolution of 900 pixels/inch for line graphs and tables and 600 pixels/inch for other image types. Please ensure that black and white figures and color figures are in Grayscale and RGB (red, green, blue) modes respectively. Figures or tables in different formats must be supplied as high-quality prints.

Please provide the corresponding author's name, the file names, the operating system (Mac or PC), as well as the compression and word processing applications used. All electronically submitted files are to be scanned by the authors for viruses with appropriate current software immediately prior to submission, and are submitted in good faith that the files are free of viruses. If there is any future concern by the authors regarding possible virus presence in previously submitted material, the Editorial Office is to be notified promptly.

Manuscripts should be sent either as e-mail attachments or on PC- or Mac-formatted CDs or DVDs. Please note that disks will not be returned. If files total more than 4.5 GB, they should be placed on a FTP server to be accessed by the Editorial Office.

All submissions must be accompanied by copies of any papers cited in the text that are accepted but not yet published, any manuscripts submitted but not yet accepted, and any related material in press or submitted elsewhere (by all co-authors). Please indicate if it is a resubmission and, if so, the name of the member of the Editorial Board to whom it was originally submitted (if not the Editorial Office). All contact with the corresponding author will be by e-mail.

Style and Organization

Language
Manuscripts are to be written in clear and concise English. Spelling should conform to either English or American usage and should be consistent throughout the paper (e.g. tumour, leukaemia, centre or tumor, leukemia, center).

Length
While there are no specific limitations regarding the length of the manuscript or the number of figures and tables, authors are strongly encouraged to be succinct.

Units
The International System of Units (SI) (http://www.nist.gov/pml/pubs/sp811/index.cfm) should be used throughout the manuscript and URLs should conform to the standard format (e.g. http://www.ebi.ac.uk/).

Superscripts, Subscripts, Symbols
To facilitate the processing of the manuscript for publication, authors are requested to format superscripts and subscripts using the Font SUPERSCRIPT and SUBSCRIPT options and symbols using the SYMBOL Font. The use of symbols in the text is restricted to:

• Greek characters
• mathematical symbols, including ± , < , >
• the symbols * , % , ® , ^TM , © , @ , ° and
• 'single' and "double" quotation marks.

Sections
All manuscripts submitted MUST have a Title page. Articles and Reviews MUST have an Abstract.

Section and subsection headings should be on separate lines and in bold.

Title Page
The publication type (Article, Review, Commentary or Reflection) should be followed by the title of the manuscript, the full first and last names of all the authors, their affiliations, mailing addresses, and e-mail addresses. If an author does not have an e-mail address, please provide a fax number. The title of the manuscript should be short, specific and informative. Superscript numbers should be used to designate institutional affiliations and a superscript asterisk (*) used to indicate joint first authorship. Please do NOT provide a running title or list of keywords. Keywords from the Medical Subject Headings from Index Medicus will be assigned by the Editorial Office.

Abstract
Summarize for a broad scientific audience. The Abstract should consist of a single paragraph not exceeding 250 words. Do NOT cite references.

Articles should also contain the following sections organized in the order shown. Reviews, Commentaries and Reflections need only include relevant sections.

Introduction
Assume that the reader is knowledgeable in the field.

Results
Present results in logical sequence in the text, tables, and illustrations. Data should be presented once, either in tables or figures, but not both. Emphasize or summarize only important observations.

Discussion
Emphasize the new and important aspects of the study and the conclusions that follow from them. Relate the observations to other relevant studies and discuss the implications of the findings and their limitations.

Abbreviations
Refer to the standard abbreviations used without definition in the journal and list nonstandard abbreviations used five or more times in the text. Define these where first mentioned in the text and do not use them in the title of the manuscript.

Acknowledgements
List any individuals who have contributed to the manuscript, along with sources of funding and material.

References
Please restrict references to published work, papers in press and Internet/Web sites closely related to the presented work. These should be cited sequentially in the text and enclosed in parentheses, e.g. (1, 2, 5-7). Personal communications, unpublished results, manuscripts submitted or in preparation should be cited as such in the text and enclosed in parentheses, i.e. (unpublished results). List references in numerical order corresponding to the order of citation in the text. References should follow the Vancouver format (http://www.icmje.org/index.html). All authors should be listed for each reference. Standard MEDLINE abbreviations for the names of journals should be used and can be found at the National Center for Biotechnology Information (NCBI) Web site journal browser at http://www.ncbi.nlm.nih.gov/nlmcatalog/journals. Identify abstracts and letters as such. Provide the complete first and last page numbers for each reference.

The PubMed ID (PMID) for references to published articles must be included in the final version to enable direct linking of references to PubMed. To find the PubMed ID for individual references, you can use the NCBI Single Citation Matcher at http://www.ncbi.nlm.nih.gov/sites/pubmedutils/citmatch (entering the date of publication and the name of the first or last author usually suffices to locate the reference). To find the PubMed ID for a series of references, use the NCBI Batch Citation Matcher at http://www.ncbi.nlm.nih.gov/sites/pubmedutils/batchcitmatch.

 

Examples of references are:

Journal article

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647. (PMID: 1840703)

Journal article, in press

2. Binder RJ, Karimedini D, Srivastava PK. Adjuvanticity of alpha₂-macroglobulin, an independent ligand for the heat shock protein receptor CD91. J Immunol 2001; in press.

Complete book

3. Janeway CA Jr, Travers P. Immunology: the immune system in health and disease. 2nd ed. New York: Garland Publishing; 1996.

Chapter in book

4. Chen YT, Scanlan MJ, Obata Y, Old LJ. Identification of human tumor antigens by serological expression cloning. In: Principles and practice of the biologic therapy of cancer. 3rd ed. Rosenberg SA. (Ed.) Philadelphia (PA): Lippincott Williams & Wilkins; 2000; 557-570.

Abstract

5. Greenberg PD, Yee C, Topp M, Bonini C, Cheng L, Cooper L, Liao M, Ohlen C, Houston Warren E, Gavin M, Riddell SR. T-cell therapy for malignant diseases - validating antigenic targets and making T cells work [abstract]. Cancer Vaccines 2000; 8: 18.

Letter to the Editor

6. Schultz H, Krenn V, Tony HP. Oligoarthritis mediated by tumor-specific T lymphocytes in renal-cell carcinoma [letter]. N Engl J Med 1999; 341: 290-291. (PMID: 10419392)

Web Site

7. ImageJ: Image processing and analysis in Java software package. URL: http://rsb.info.nih.gov/ij/

Materials and Methods
A statement that all experiments were performed in compliance with institutional guidelines and relevant laws and identifying the committee(s) that have approved the experiments must be included for papers reporting experiments involving live animals or human subjects. Papers presenting research involving human subjects must also include a statement that informed consent was obtained from each subject or subject's guardian. The trial registration number for the trial being reported, as well as for any other trials mentioned in the manuscript, should be provided so that a link to the registry can be provided whenever possible. Names and addresses of suppliers of uncommon reagents or instruments should be provided. Refer to published methods wherever possible, and clearly describe new or substantially modified methods.

Contact
The complete mailing address, telephone number, fax number and e-mail address of the corresponding author should also be provided. Unless otherwise requested by the corresponding author, this information will appear online, with the e-mail address encrypted.

Figure Legends
List legends in the order of appearance. Provide a brief descriptive title in bold and a detailed legend. Explain any abbreviations in tables using footnotes indicated by lower case letters (e.g. a, b, c). ALL symbols used in figures, other than accepted symbols, must be described using words in the legend or defined in an inset within the figure.

Tables and Figures
Number tables and figures consecutively, but separately, with Arabic numerals. Tables and figures are to be submitted separately from the text at the desired printed size, with clearly legible numbers, letters, and symbols. Each table or figure should be no larger than 20.3 cm (8 inches) wide and 25.4 cm (10 inches) high. The use of color is encouraged where it improves clarity, e.g. for comparative sequence data. Avoid wide variation in type size within a single table or figure. Figures and tables will NOT be redrawn or relabeled.

Tables should have a brief descriptive title. Any additional relevant comments should be included as footnotes to the table. Units of measure should be included in parentheses in column headings or axes; units should not change within a column or axis.

Please ensure that figures do NOT have a frame. Composite figures should be labeled A, B, C and submitted as one figure. Any lettering or text should be in proportion with the rest of the figure. Use boldface type for axis labels and for labels in composite figures. For graphs, use powers of 10 for scales with large or small numbers.

Supplemental Data
Supplemental Data may take the form of supporting figures, tables, datasets, databases, and videos. Whenever possible, supplemental data file formats should be platform-independent and proprietary software-independent. A brief description of the data should be provided for each supplemental data file. Please contact the Editorial Office to discuss the submission and format of such data.

Accepted Manuscripts

Upon acceptance for publication, the corresponding author must submit the text of the final version electronically to the Editorial Office. If necessary, the corresponding author will be asked to supply all figures and complex tables as high-quality, glossy prints so that they can be scanned. The manuscript, figures and tables should include any modifications requested by the reviewers. No charges are levied for handling of the manuscript.

Written permission to cite accepted or submitted manuscripts along with verification that they have been accepted for publication must be provided by the authors. Written permission and confirmation of accuracy from the source of any personal communications cited in the paper must also be provided. Statements that the manuscript has been read and approved by all the authors, that each author believes that the manuscript represents honest work, and that the contents of the manuscript have not been previously published, must accompany the manuscript. Sequence and structural data must be deposited with the appropriate data bank prior to publication, and the corresponding entries must be provided for inclusion in the published manuscript. Clinical trial registry number(s) must be provided for all clinical trails cited in the manuscript.

The corresponding author is responsible for communicating with the other authors about revisions and final approval of the proofs. Unless otherwise requested, copyright to the material published in the journal will be attributed to the corresponding author.

Proofs

Authors should bear in mind that manuscripts may be altered in the publishing process to conform to the journal's publication style. Prior to publication, the corresponding author will be e-mailed the proofs in PDF format. Any errors should be reported to the Editorial Office within 2 working days. Papers will appear online within 72 hours of receipt of corrections. Major alterations will delay publication beyond this timeframe.

Publication

All papers are published exclusively online. Each paper constitutes a separate page of a yearly volume. An "abstract only" and a "full text" version in HTML format, as well as a "printer-friendly" PDF version, are posted.

Cancer Immunity is indexed by MEDLINE. New papers are indexed within a few days of their appearance on the journal's Web site. All papers are accessible through the NCBI's PubMed Web pages.

Published articles are deposited in PubMed Central (PMC), the free digital archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health (NIH). Papers are accessible through the NCBI's PubMed Central Web pages.

Errata

After online publication, further changes can only be made in the form of an Erratum or a Retraction, which will be hyperlinked to the original publication. Errors which do not affect the overall basic results or conclusions of a published article are published in the form of an Erratum. Errors that may call into question the source of the data or the validity of the results and conclusions of an article are published in the form of a Retraction. Errata and Retractions are published with the consent of all of the authors of the original publication and the Editor who conducted the review of the original manuscript. However, the journal will publish a Retraction without the authors' consent upon notification by the funding agency or sponsoring institution that research published in the journal was found to be fraudulent or upon determining that duplicate publication has taken place.